CCM
TGTX icon

Chiron Capital Management’s TG Therapeutics TGTX Stock Holding History

Chiron Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,500
Closed -$236K – 127
2023
Q2 		$236K Sell
9,500
-2,600
-21% -$67.2K 0.19% 91
2023
Q1 		$182K Buy
12,100
+1,483
+14% +$22.5K 0.13% 113
2022
Q4 		$126K Buy
+10,617
New +$77.1K 0.09% 117
2022
Q3 		– Sell
-10,717
Closed -$46K – 130
2022
Q2 		$46K Sell
10,717
-2,975
-22% -$18.6K 0.03% 125
2022
Q1 		$130K Buy
13,692
+1,920
+16% +$22.2K 0.08% 118
2021
Q4 		$224K Buy
+11,772
New +$306K 0.16% 102
2020
Q4 		– Sell
-4,425
Closed -$118K – 404
2020
Q3 		$118K Buy
+4,425
New +$102K 0.1% 96

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Chiron Capital Management's TGTX Position: Q3 2023 in Review

Chiron Capital Management sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 9,500 shares — an estimated $236K sold.

Chiron Capital Management first reported a position in TGTX in Q3 2020 and held it in 7 quarters. The position peaked at $236K in Q2 2023. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Chiron Capital Management reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Chiron Capital Management sold 9,500 TG Therapeutics shares in Q3 2023, an estimated $236K.
  • Chiron Capital Management first reported a position in TG Therapeutics in Q3 2020 and held it in 7 quarters.
  • Chiron Capital Management's TG Therapeutics position peaked at $236K in Q2 2023.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Chiron Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.